7342. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
作者: Peter Chen.;Ajay Nirula.;Barry Heller.;Robert L Gottlieb.;Joseph Boscia.;Jason Morris.;Gregory Huhn.;Jose Cardona.;Bharat Mocherla.;Valentina Stosor.;Imad Shawa.;Andrew C Adams.;Jacob Van Naarden.;Kenneth L Custer.;Lei Shen.;Michael Durante.;Gerard Oakley.;Andrew E Schade.;Janelle Sabo.;Dipak R Patel.;Paul Klekotka.;Daniel M Skovronsky.; .
来源: N Engl J Med. 2021年384卷3期229-237页
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.
7348. Dexamethasone in Hospitalized Patients with Covid-19.
作者: .;Peter Horby.;Wei Shen Lim.;Jonathan R Emberson.;Marion Mafham.;Jennifer L Bell.;Louise Linsell.;Natalie Staplin.;Christopher Brightling.;Andrew Ustianowski.;Einas Elmahi.;Benjamin Prudon.;Christopher Green.;Timothy Felton.;David Chadwick.;Kanchan Rege.;Christopher Fegan.;Lucy C Chappell.;Saul N Faust.;Thomas Jaki.;Katie Jeffery.;Alan Montgomery.;Kathryn Rowan.;Edmund Juszczak.;J Kenneth Baillie.;Richard Haynes.;Martin J Landray.
来源: N Engl J Med. 2021年384卷8期693-704页
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
|